JP2018518486A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518486A5
JP2018518486A5 JP2017563541A JP2017563541A JP2018518486A5 JP 2018518486 A5 JP2018518486 A5 JP 2018518486A5 JP 2017563541 A JP2017563541 A JP 2017563541A JP 2017563541 A JP2017563541 A JP 2017563541A JP 2018518486 A5 JP2018518486 A5 JP 2018518486A5
Authority
JP
Japan
Prior art keywords
compound
obtaining
reacted
give
give compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017563541A
Other languages
English (en)
Other versions
JP6873053B2 (ja
JP2018518486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/036434 external-priority patent/WO2016200930A1/en
Publication of JP2018518486A publication Critical patent/JP2018518486A/ja
Publication of JP2018518486A5 publication Critical patent/JP2018518486A5/ja
Application granted granted Critical
Publication of JP6873053B2 publication Critical patent/JP6873053B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (17)

  1. 以下の工程を含む、化合物(Ia)の製造方法:
    (1)化合物1a:
    Figure 2018518486
    をアニリン及び酸と反応させ、化合物11a:
    Figure 2018518486
    [式中、
    Xはフッ素、塩素、臭素及びヨウ素から選択され;
    Zは−CN及び−CORから成る群から選択され;及び
    RはC−Cアルキルである]
    を形成する工程;
    (2)化合物11aを元素銅の存在下でヨードベンゼンと反応させ、化合物3a:
    Figure 2018518486
    を得る工程;
    (3)化合物3aを水と反応させ、化合物4a:
    Figure 2018518486
    を得る工程;
    (4)化合物4aをヒドロキシベンゾトリアゾールの存在下でアルキルアミンと反応させ、化合物5a:
    Figure 2018518486
    [式中、
    R’はC−Cアルキルである]
    を得る工程;並びに
    (5)化合物5aをアルコキシド塩基と反応させ、化合物(Ia):
    Figure 2018518486
    またはその塩を得る工程。
  2. ZがCOEtである、請求項1に記載の方法。
  3. R’がメチルである、請求項1に記載の方法。
  4. 化合物11aを得る工程が、化合物1a:
    Figure 2018518486
    をアニリン及び酸と反応させ、その後塩基によって脱プロトン化して、化合物11a:
    Figure 2018518486
    を形成する工程をさらに含む、請求項1に記載の方法。
  5. 化合物3aを得る工程が、化合物11a:
    Figure 2018518486
    を元素銅及び塩基の存在下でヨードベンゼンと反応させ、化合物3a:
    Figure 2018518486
    を得る工程をさらに含む、請求項1に記載の方法。
  6. 化合物4aを得る工程が、化合物3a:
    Figure 2018518486
    を水と反応させ、その後酸と反応させ、化合物4a:
    Figure 2018518486
    を得る工程をさらに含む、請求項1に記載の方法。
  7. 化合物5aを得る工程が、化合物4a:
    Figure 2018518486
    をヒドロキシベンゾトリアゾール及び1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミドの存在下でアルキルアミンと反応させ、化合物5a:
    Figure 2018518486
    を得る工程をさらに含む、請求項1に記載の方法。
  8. 化合物(Ia)を得る工程が、化合物5a:
    Figure 2018518486
    をヒドロキシルアミン塩酸塩の存在下でアルコキシド塩基と反応させ、化合物(Ia):
    Figure 2018518486
    またはその塩を得る工程をさらに含む、請求項1に記載の方法。
  9. 以下の工程を含む、化合物(I)の製造方法:
    (1)化合物1b:
    Figure 2018518486
    を2−クロロアニリン及び酸と反応させ、化合物11b:
    Figure 2018518486
    [式中、
    Zは−CN及び−CORから成る群から選択され;及び
    RはC−Cアルキルである]
    を形成する工程;
    (2)化合物11bを元素銅の存在下でヨードベンゼンと反応させ、化合物3b:
    Figure 2018518486
    を得る工程;
    (3)化合物3bを水と反応させ、化合物4:
    Figure 2018518486
    を得る工程;
    (4)化合物4をヒドロキシベンゾトリアゾールの存在下でアルキルアミンと反応させ、化合物5b:
    Figure 2018518486
    [式中、
    R’はC−Cアルキルである]
    を得る工程;並びに
    (5)化合物5bをアルコキシド塩基と反応させ、化合物(I):
    Figure 2018518486
    またはその塩を得る工程。
  10. ZがCOEtである、請求項9に記載の方法。
  11. R’がメチルである、請求項9に記載の方法。
  12. 化合物11bを得る工程が、化合物1b:
    Figure 2018518486
    を2−クロロアニリン及び酸と反応させ、その後塩基によって脱プロトン化して、化合物11b:
    Figure 2018518486
    を形成する工程をさらに含む、請求項9に記載の方法。
  13. 化合物3bを得る工程が、化合物11b:
    Figure 2018518486
    を元素銅及び塩基の存在下でヨードベンゼンと反応させ、化合物3b:
    Figure 2018518486
    を得る工程をさらに含む、請求項9に記載の方法。
  14. 化合物4を得る工程が、化合物3b:
    Figure 2018518486
    を水と反応させ、その後酸と反応させ、化合物4:
    Figure 2018518486
    を得る工程をさらに含む、請求項9に記載の方法。
  15. 化合物5bを得る工程が、化合物4:
    Figure 2018518486
    をヒドロキシベンゾトリアゾール及び1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミドの存在下でアルキルアミンと反応させ、化合物5b:
    Figure 2018518486
    を得る工程をさらに含む、請求項9に記載の方法。
  16. 化合物(I)を得る工程が、化合物5b:
    Figure 2018518486
    をヒドロキシルアミン塩酸塩の存在下でアルコキシド塩基と反応させ、化合物(I):
    Figure 2018518486
    またはその塩を得る工程をさらに含む、請求項9に記載の方法。
  17. 以下の工程を含む、化合物(I)の製造方法:
    (1)2−クロロピリミジン−5−カルボン酸エチルをアルコール溶媒の存在下で2−クロロアニリンと反応させ、化合物11
    Figure 2018518486
    を得る工程:
    (2)化合物11を元素銅の存在下でヨードベンゼンと反応させ化合物3
    Figure 2018518486
    を得る工程:
    (3)化合物3を水と反応させ、その後酸と反応させ、化合物4
    Figure 2018518486
    を得る工程:
    (4)化合物4をヒドロキシベンゾトリアゾール及び1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミドの存在下で7−アミノヘプタン酸メチルと反応させ、化合物5:
    Figure 2018518486
    を得る工程;
    (5)化合物5をアルコール溶媒の存在下でヒドロキシルアミンまたはその塩及びアルコキシド塩基と反応させ、化合物(I):
    Figure 2018518486
    またはその塩を得る工程。
JP2017563541A 2015-06-08 2016-06-08 タンパク質脱アセチル化阻害剤の製造方法 Active JP6873053B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562172624P 2015-06-08 2015-06-08
US62/172,624 2015-06-08
PCT/US2016/036434 WO2016200930A1 (en) 2015-06-08 2016-06-08 Methods of making protein deacetylase inhibitors

Publications (3)

Publication Number Publication Date
JP2018518486A JP2018518486A (ja) 2018-07-12
JP2018518486A5 true JP2018518486A5 (ja) 2019-07-04
JP6873053B2 JP6873053B2 (ja) 2021-05-19

Family

ID=56264043

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017563541A Active JP6873053B2 (ja) 2015-06-08 2016-06-08 タンパク質脱アセチル化阻害剤の製造方法

Country Status (11)

Country Link
US (1) US10144714B2 (ja)
EP (1) EP3303304B1 (ja)
JP (1) JP6873053B2 (ja)
CN (1) CN107922352B (ja)
AR (1) AR105812A1 (ja)
AU (2) AU2016276573A1 (ja)
CA (1) CA2988594C (ja)
ES (1) ES2769255T3 (ja)
MX (1) MX369349B (ja)
TW (1) TWI706937B (ja)
WO (1) WO2016200930A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2526093T (pt) * 2010-01-22 2016-11-25 Acetylon Pharmaceuticals Inc Compostos amida reversa como inibidores de proteína desacetilase e métodos de utilização dos mesmos
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
AR104935A1 (es) 2015-06-08 2017-08-23 Acetylon Pharmaceuticals Inc Formas cristalinas de un inhibidor de histona deacetilasa
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
EP3468559B1 (en) * 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
WO2018031472A1 (en) 2016-08-08 2018-02-15 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof
WO2018098168A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
PT1442019E (pt) 2001-11-01 2007-12-11 Janssen Pharmaceutica Nv Derivados de amida como inibidores da glicogénio sintase cinase 3-beta
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1644323B1 (en) 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
EP1745022B1 (en) 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
EP3354265A1 (en) 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
WO2007022638A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
JP5563300B2 (ja) 2006-09-11 2014-07-30 キュリス,インコーポレイテッド 亜鉛結合部分を含むチロシンキナーゼインヒビター
US8778410B2 (en) 2008-02-19 2014-07-15 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US20130040998A1 (en) 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof
PT2526093T (pt) * 2010-01-22 2016-11-25 Acetylon Pharmaceuticals Inc Compostos amida reversa como inibidores de proteína desacetilase e métodos de utilização dos mesmos
AU2011255281A1 (en) 2010-05-21 2013-01-10 Sloan-Kettering Institute For Cancer Research Selective HDAC inhibitors
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
ES2568260T3 (es) 2010-11-16 2016-04-28 Acetylon Pharmaceuticals, Inc. Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos
JP6169076B2 (ja) 2011-07-20 2017-07-26 ザ ジェネラル ホスピタル コーポレイション 骨疾患の処置のためのヒストン脱アセチル化酵素6選択的阻害剤
US8841301B2 (en) * 2011-09-26 2014-09-23 Bristol-Myers Squibb Company Selective NR2B antagonists
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US20150250786A1 (en) 2012-10-12 2015-09-10 The Trustees Of The University Of Pennsylvania Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9096549B2 (en) 2013-02-01 2015-08-04 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
JP2016523236A (ja) 2013-06-03 2016-08-08 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. 多発性骨髄腫におけるヒストン脱アセチル化酵素(hdac)バイオマーカー
EP3046559A4 (en) 2013-09-20 2017-03-22 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
US20150105409A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma
WO2015054355A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
EP3055299B1 (en) 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
EP3054939A4 (en) 2013-10-11 2017-12-13 Acetylon Pharmaceuticals, Inc. Combinations of histone deactylase inhibitors and immunomodulatory drugs
EP4137135A1 (en) 2013-10-24 2023-02-22 Mayo Foundation for Medical Education and Research Treatment of polycystic diseases with an hdac6 inhibitor
MX2016007251A (es) 2013-12-03 2016-09-07 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores.
JP7017309B2 (ja) 2013-12-20 2022-02-08 アセチロン ファーマシューティカルズ インコーポレイテッド 多発性骨髄腫におけるヒストン脱アセチル化酵素6(hdac6)バイオマーカー
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
AU2015288060A1 (en) 2014-07-07 2017-02-09 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
CA2963681A1 (en) 2014-10-08 2016-04-14 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
US20160158231A1 (en) 2014-12-05 2016-06-09 Vib Vzw Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
ES2816641T3 (es) 2014-12-12 2021-04-05 Regenacy Pharmaceuticals Inc Derivados de piperidina en calidad de inhibidores de HDAC1/2
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
AR104935A1 (es) 2015-06-08 2017-08-23 Acetylon Pharmaceuticals Inc Formas cristalinas de un inhibidor de histona deacetilasa
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
WO2018031472A1 (en) 2016-08-08 2018-02-15 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2018518486A5 (ja)
JP2013505259A5 (ja)
RU2016110024A (ru) Некоторые химические соединения, композиции и способы
JP2018529687A5 (ja)
JP2009527517A5 (ja)
JP2018522018A5 (ja)
JP2019048806A5 (ja)
RU2016133187A (ru) Способ получения n-[(3-аминооксетан-3-ил)метил]-2-(1,1-диоксо-3,5-дигидро-1,4-бензотиазепин-4ил)-6-метил-хиназолин-4-амина
JP2018526340A5 (ja)
JP2019504839A5 (ja)
JP2022160672A5 (ja)
JP2016188255A5 (ja)
JP2018524387A5 (ja)
JP2015523382A5 (ja)
JP2013520413A5 (ja)
JP2018009003A5 (ja)
JP2019508387A5 (ja)
RU2012139082A (ru) Способы получения производных циклопропиламида и связанных с ними промежуточных соединений
JP2018507858A5 (ja)
JP7232618B2 (ja) アコチアミドの改善された製造方法
JP2016539168A5 (ja)
JP2015524806A5 (ja)
TW201833065A (zh) 製備經環丙基取代之苯乙酮的方法
JP2010132661A5 (ja)
JP2015535210A5 (ja)